I have been prescribed Xarelto® (rivaroxaban) to either treat DVT or PE, or prevent them from recurring

How to transition to Xarelto?

You have decided with your doctor to transition from warfarin to a Non-VKA Oral Anti-Coagulant (NOAC). This medical information is intended specifically for UK patients transitioning to Xarelto. It is not intended to substitute clinical judgement discussed between you and your healthcare professional.

Transitioning from warfarin to Xarelto is not suitable for every patient. This change to your prescription medication should only be made by your doctor after clinical assessment.

When Xarelto is initiated, then this should be done when your International Normalised Ratio (INR) levels are ≤ 2.5.

You should always take your medication exactly as your doctor has advised you to ensure this medication is working effectively for you. Please take great care not to accidentally take both warfarin and Xarelto together. Refer to the Xarelto Patient Information Leaflet for more information.

To access the latest version of the Xarelto 2.5mg, 10mg and 15/20 mg Summary of Product Characteristics (SmPC) as well as Xarelto Patient Information Leaflet (PIL), please click on the following link eMC Widget

Report Possible Side Effects

This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store.

You can also report side effects and quality complaints to Bayer Plc. Further information is available on the “contact” tab at www.bayer.co.uk.

By reporting side effects you can help provide more information on the safety of this medicine.